How GIP Works in Tirzepatide — and Why It Matters for Weight Loss

Step 1: what GIP is and what it normally does

Your small intestine releases GIP within minutes of a meal arriving. Under normal circumstances, this hormone has two main jobs. It signals the pancreas to release insulin when blood glucose is rising, only then, which is why it is described as glucose-dependent and why it doesn't cause dangerous drops in blood sugar on its own. It also appears to act on fat cells, influencing how they store and process energy. For a long time, GIP was considered the less glamorous sibling of GLP-1 in metabolic research, partly because early evidence suggested GIP's insulin-signalling effect was blunted in people with type 2 diabetes. Tirzepatide's development changed that thinking. Eli Lilly found that activating the GIP receptor with a purpose-built molecule, alongside GLP-1 stimulation, produced results that neither pathway delivered individually. The clinical significance of the GIP receptor in tirzepatide is now one of the more closely studied questions in metabolic medicine. GIP's actions in the brain, particularly in areas linked to appetite and reward, are also under active investigation, the receptor is present in the hypothalamus, which helps regulate hunger signals.

Step 2: how tirzepatide binds to the GIP receptor and what happens next

Tirzepatide is a synthetic peptide molecule engineered to fit both the GIP and GLP-1 receptors with high affinity. When you inject your weekly dose and it enters the bloodstream, it begins binding to GIP receptors across several tissues simultaneously. In the pancreas, GIP receptor activation supports insulin secretion in a glucose-dependent way, a point worth dwelling on, because it means the mechanism has a natural safety brake that kicks in when blood glucose is not elevated. In adipose tissue, GIP receptor signalling appears to influence fat metabolism; exactly how this contributes to weight reduction is still being clarified by ongoing research. In the brain, activation of central GIP receptors is thought to complement the appetite-suppressing effect of GLP-1 receptor binding. The net result, seen in clinical trials, is a level of appetite reduction and caloric intake reduction that exceeds what GLP-1 agonism alone has historically produced. You can read more about the full receptor picture on the detailed mechanism page. Tirzepatide is dispensed as a once-weekly injection, and the starting dose of 2.5mg exists to let your system adjust gradually before the prescriber considers increasing it.

Step 3: why the dual-agonist design may explain tirzepatide's clinical results

The SURMOUNT-1 trial, published in the New England Journal of Medicine, randomised 2,539 adults with obesity and found average body-weight reductions of around 20–21% at the 15mg dose over 72 weeks, a figure that stands ahead of what earlier GLP-1-only medicines produced in comparable trials. The SURMOUNT-5 head-to-head trial, published in the NEJM in 2025, confirmed that tirzepatide produced greater average weight loss than semaglutide 2.4mg in adults with obesity who did not have diabetes. Researchers attribute at least part of this difference to GIP receptor engagement. Whether the GIP pathway acts independently, synergistically with GLP-1, or through indirect mechanisms is still being unpicked. What the trial data shows clearly is that the combination outperforms single-pathway stimulation. NICE's appraisal of tirzepatide (TA1026, published December 2024) referenced this evidence base when recommending the medicine for eligible adults with obesity in England. The Mounjaro overview page covers how those eligibility criteria apply in practice.

Step 4: what this means if you are considering tirzepatide

If you want to understand how Mounjaro works at a receptor level, including why its dual-agonist design sets it apart from earlier weight loss medicines, that detail is worth reading before you start a consultation. It also underscores that this is a pharmacologically complex prescription medicine, not a supplement. The NHS summarises tirzepatide's pharmacology clearly on its tirzepatide medicine page, and the full SmPC is available via the eMC for anyone who wants the technical detail. A pharmacist-prescriber at a regulated service reads each consultation in full, a real clinician, not an automated system, makes the clinical judgement. Cost is sometimes a factor when people explore their options; the Eli Lilly UK price increase page sets out the market context honestly. If tirzepatide sounds like something you want to explore, the right starting point is a clinical conversation about whether your health profile makes it suitable. Our prescribers are straightforward about this. Check your eligibility by starting a free consultation at our treatment page, it's reviewed the same day by a GPhC-registered prescriber.